Neil A Goldenberg1,2,3, John M Kittelson4,5, Thomas C Abshire6, Marc Bonaca5,7, James F Casella2, Rita A Dale5, Jonathan L Halperin8, Frances Hamblin1, Craig M Kessler9, Marilyn J Manco-Johnson10, Robert F Sidonio11, Alex C Spyropoulos12,13, P Gabriel Steg14, Alexander G G Turpie15, Sam Schulman13,15. 1. Institute for Clinical and Translational Research, Cancer and Blood Disorder Institute, and Heart Institute, Johns Hopkins All Children's Hospital, St Petersburg, Florida. 2. Department of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 3. Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland. 4. Department of Biostatistics, School of Public Health, University of Colorado Anschutz Medical Campus, Aurora. 5. CPC Clinical Research, Aurora, Colorado. 6. Versiti Blood Research Institute and Department of Pediatrics and Medicine and Clinical and Translational Science Institute, Medical College of Wisconsin, Milwaukee. 7. Division of Cardiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora. 8. Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 9. Lombardi Cancer Center, Department of Medicine, School of Medicine, Georgetown University, Washington, DC. 10. Department of Pediatrics, School of Medicine, Children's Hospital of Colorado, Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora. 11. Department of Pediatrics, Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, Georgia. 12. Department of Medicine, Zucker School of Medicine at Hofstra/Northwell and Feinstein Institutes for Medical Research, Manhasset, New York. 13. Department of Obstetrics and Gynecology, I. M. Sechenov First Moscow State Medical University, Moscow, Russia. 14. Université de Paris, AP-HP, Hôpital Bichat, French Alliance for Cardiovascular Trials and INSERM 1148, Paris, France. 15. Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada.
Abstract
Importance: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown. Objective: To test the hypothesis that a 6-week duration of anticoagulant therapy for provoked venous thromboembolism is noninferior to a conventional 3-month therapy duration in patients younger than 21 years of age. Design, Setting, and Participants: Randomized clinical trial involving 417 patients younger than 21 years of age with acute, provoked venous thromboembolism enrolled at 42 centers in 5 countries from 2008-2021. The main exclusions were severe anticoagulant deficiencies or prior venous thromboembolism. Patients without persistent antiphospholipid antibodies and whose thrombi were resolved or not completely occlusive upon repeat imaging at 6 weeks after diagnosis underwent randomization. The final visit for the primary end points occurred in January 2021. Interventions: Total duration for anticoagulant therapy of 6 weeks (n = 207) vs 3 months (n = 210) for provoked venous thromboembolism. Main Outcomes and Measures: The primary efficacy and safety end points were centrally adjudicated symptomatic recurrent venous thromboembolism and clinically relevant bleeding events within 1 year blinded to treatment group. The primary analysis was noninferiority in the per-protocol population. The noninferiority boundary incorporated a bivariate trade-off that included an absolute increase of 0% in symptomatic recurrent venous thromboembolism with an absolute risk reduction of 4% in clinically relevant bleeding events (1 of 3 points on the bivariate noninferiority boundary curve). Results: Among 417 randomized patients, 297 (median age, 8.3 [range, 0.04-20.9] years; 49% female) met criteria for the primary per-protocol population analysis. The Kaplan-Meier estimate for the 1-year cumulative incidence of the primary efficacy outcome was 0.66% (95% CI, 0%-1.95%) in the 6-week anticoagulant therapy group and 0.70% (95% CI, 0%-2.07%) in the 3-month anticoagulant therapy group, and for the primary safety outcome, the incidence was 0.65% (95% CI, 0%-1.91%) and 0.70% (95% CI, 0%-2.06%). Based on absolute risk differences in recurrent venous thromboembolism and clinically relevant bleeding events between groups, noninferiority was demonstrated. Adverse events occurred in 26% of patients in the 6-week anticoagulant therapy group and in 32% of patients in the 3-month anticoagulant therapy group; the most common adverse event was fever (1.9% and 3.4%, respectively). Conclusions and Relevance: Among patients younger than 21 years of age with provoked venous thromboembolism, anticoagulant therapy for 6 weeks compared with 3 months met noninferiority criteria based on the trade-off between recurrent venous thromboembolism risk and bleeding risk. Trial Registration: ClinicalTrials.gov Identifier: NCT00687882.
Importance: Among patients younger than 21 years of age, the optimal duration of anticoagulant therapy for venous thromboembolism is unknown. Objective: To test the hypothesis that a 6-week duration of anticoagulant therapy for provoked venous thromboembolism is noninferior to a conventional 3-month therapy duration in patients younger than 21 years of age. Design, Setting, and Participants: Randomized clinical trial involving 417 patients younger than 21 years of age with acute, provoked venous thromboembolism enrolled at 42 centers in 5 countries from 2008-2021. The main exclusions were severe anticoagulant deficiencies or prior venous thromboembolism. Patients without persistent antiphospholipid antibodies and whose thrombi were resolved or not completely occlusive upon repeat imaging at 6 weeks after diagnosis underwent randomization. The final visit for the primary end points occurred in January 2021. Interventions: Total duration for anticoagulant therapy of 6 weeks (n = 207) vs 3 months (n = 210) for provoked venous thromboembolism. Main Outcomes and Measures: The primary efficacy and safety end points were centrally adjudicated symptomatic recurrent venous thromboembolism and clinically relevant bleeding events within 1 year blinded to treatment group. The primary analysis was noninferiority in the per-protocol population. The noninferiority boundary incorporated a bivariate trade-off that included an absolute increase of 0% in symptomatic recurrent venous thromboembolism with an absolute risk reduction of 4% in clinically relevant bleeding events (1 of 3 points on the bivariate noninferiority boundary curve). Results: Among 417 randomized patients, 297 (median age, 8.3 [range, 0.04-20.9] years; 49% female) met criteria for the primary per-protocol population analysis. The Kaplan-Meier estimate for the 1-year cumulative incidence of the primary efficacy outcome was 0.66% (95% CI, 0%-1.95%) in the 6-week anticoagulant therapy group and 0.70% (95% CI, 0%-2.07%) in the 3-month anticoagulant therapy group, and for the primary safety outcome, the incidence was 0.65% (95% CI, 0%-1.91%) and 0.70% (95% CI, 0%-2.06%). Based on absolute risk differences in recurrent venous thromboembolism and clinically relevant bleeding events between groups, noninferiority was demonstrated. Adverse events occurred in 26% of patients in the 6-week anticoagulant therapy group and in 32% of patients in the 3-month anticoagulant therapy group; the most common adverse event was fever (1.9% and 3.4%, respectively). Conclusions and Relevance: Among patients younger than 21 years of age with provoked venous thromboembolism, anticoagulant therapy for 6 weeks compared with 3 months met noninferiority criteria based on the trade-off between recurrent venous thromboembolism risk and bleeding risk. Trial Registration: ClinicalTrials.gov Identifier: NCT00687882.
Authors: S Revel-Vilk; L R Brandão; J Journeycake; N A Goldenberg; A Goldenberg; P Monagle; A Sharathkumar; A K C Chan Journal: J Thromb Haemost Date: 2012-10 Impact factor: 5.824
Authors: N A Goldenberg; T Abshire; P J Blatchford; L Z Fenton; J L Halperin; W R Hiatt; C M Kessler; J M Kittelson; M J Manco-Johnson; A C Spyropoulos; P G Steg; N V Stence; A G G Turpie; S Schulman Journal: J Thromb Haemost Date: 2015-08-11 Impact factor: 5.824
Authors: Paul Monagle; Carlos A Cuello; Caitlin Augustine; Mariana Bonduel; Leonardo R Brandão; Tammy Capman; Anthony K C Chan; Sheila Hanson; Christoph Male; Joerg Meerpohl; Fiona Newall; Sarah H O'Brien; Leslie Raffini; Heleen van Ommen; John Wiernikowski; Suzan Williams; Meha Bhatt; John J Riva; Yetiani Roldan; Nicole Schwab; Reem A Mustafa; Sara K Vesely Journal: Blood Adv Date: 2018-11-27
Authors: John M Kittelson; Philippe Gabriel Steg; Jonathan L Halperin; Neil A Goldenberg; Sam Schulman; Alex C Spyropoulos; Craig M Kessler; Alexander G G Turpie; Neal R Cutler; William R Hiatt Journal: Thromb Haemost Date: 2016-06-23 Impact factor: 5.249
Authors: J M Kittelson; A C Spyropoulos; J L Halperin; C M Kessler; S Schulman; G Steg; A G G Turpie; N R Cutler; W R Hiatt; N A Goldenberg Journal: J Thromb Haemost Date: 2013-08 Impact factor: 5.824
Authors: Paul Monagle; Elizabeth Chalmers; Anthony Chan; Gabrielle deVeber; Fenella Kirkham; Patricia Massicotte; Alan D Michelson Journal: Chest Date: 2008-06 Impact factor: 9.410
Authors: Susan R Kahn; Ian Shrier; Jim A Julian; Thierry Ducruet; Louise Arsenault; Marie-José Miron; Andre Roussin; Sylvie Desmarais; France Joyal; Jeannine Kassis; Susan Solymoss; Louis Desjardins; Donna L Lamping; Mira Johri; Jeffrey S Ginsberg Journal: Ann Intern Med Date: 2008-11-18 Impact factor: 25.391